Advertisement

Effect of Ezetimibe on Major Atherosclerotic Disease Events and All-Cause Mortality

Published:December 07, 2012DOI:https://doi.org/10.1016/j.amjcard.2012.11.002
      Despite ezetimibe’s ability to reduce serum cholesterol levels, there are concerns over its vascular effects and whether it prevents or ameliorates atherosclerotic disease (AD). The aims of this study were to estimate the effect of ezetimibe use on major AD events and all-cause mortality and to compare these associations to those observed for hydroxymethylglutaryl coenzyme A reductase inhibitor (statin) use. A total of 367 new ezetimibe users were identified from November 1, 2002, to December 31, 2009. These subjects were aged ≥18 years and had no previous statin use. One to 4 statin user matches were identified for each ezetimibe user, resulting in a total of 1,238 closely matched statin users. Pharmacy data and drug dosage information were used to estimate a moving window of ezetimibe and statin exposure for each day of study follow-up. The primary outcome was a composite of major AD events (coronary heart disease, cerebrovascular disease, and peripheral vascular disease events) and all-cause death. Ezetimibe use (odds ratio 0.33, 95% confidence interval 0.13 to 0.86) and statin use (odds ratio 0.61, 95% confidence interval 0.36 to 1.04) were associated with reductions in the likelihood of the composite outcome. These protective associations were most significant for cerebrovascular disease events and all-cause death. Subgroup analyses by gender, race or ethnicity, history of AD, diabetes status, and estimated renal function showed consistent estimates across strata, with no significant differences between ezetimibe and statin use. In conclusion, ezetimibe appeared to have a protective effect on major AD events and all-cause death that was not significantly different from that observed for statin use.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fleg J.L.
        • Mete M.
        • Howard B.V.
        • Umans J.G.
        • Roman M.J.
        • Ratner R.E.
        • Silverman A.
        • Galloway J.M.
        • Henderson J.A.
        • Weir M.R.
        • Wilson C.
        • Stylianou M.
        • Howard W.J.
        Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.
        J Am Coll Cardiol. 2008; 52: 2198-2205
        • Kastelein J.J.
        • Akdim F.
        • Stroes E.S.
        • Zwinderman A.H.
        • Bots M.L.
        • Stalenhoef A.F.
        • Visseren F.L.
        • Sijbrands E.J.
        • Trip M.D.
        • Stein E.A.
        • Gaudet D.
        • Duivenvoorden R.
        • Veltri E.P.
        • Marais A.D.
        • de G.E.
        Simvastatin with or without ezetimibe in familial hypercholesterolemia.
        N Engl J Med. 2008; 358: 1431-1443
        • Taylor A.J.
        • Villines T.C.
        • Stanek E.J.
        • Devine P.J.
        • Griffen L.
        • Miller M.
        • Weissman N.J.
        • Turco M.
        Extended-release niacin or ezetimibe and carotid intima-media thickness.
        N Engl J Med. 2009; 361: 2113-2122
        • Baigent C.
        • Landray M.J.
        • Reith C.
        • Emberson J.
        • Wheeler D.C.
        • Tomson C.
        • Wanner C.
        • Krane V.
        • Cass A.
        • Craig J.
        • Neal B.
        • Jiang L.
        • Hooi L.S.
        • Levin A.
        • Agodoa L.
        • Gaziano M.
        • Kasiske B.
        • Walker R.
        • Massy Z.A.
        • Feldt-Rasmussen B.
        • Krairittichai U.
        • Ophascharoensuk V.
        • Fellstrom B.
        • Holdaas H.
        • Tesar V.
        • Wiecek A.
        • Grobbee D.
        • de Z.D.
        • Gronhagen-Riska C.
        • Dasgupta T.
        • Lewis D.
        • Herrington W.
        • Mafham M.
        • Majoni W.
        • Wallendszus K.
        • Grimm R.
        • Pedersen T.
        • Tobert J.
        • Armitage J.
        • Baxter A.
        • Bray C.
        • Chen Y.
        • Chen Z.
        • Hill M.
        • Knott C.
        • Parish S.
        • Simpson D.
        • Sleight P.
        • Young A.
        • Collins R.
        The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
        Lancet. 2011; 377: 2181-2192
        • Habib Z.A.
        • Tzogias L.
        • Havstad S.L.
        • Wells K.
        • Divine G.
        • Lanfear D.E.
        • Tang J.
        • Krajenta R.
        • Pladevall M.
        • Williams L.K.
        Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
        Pharmacoepidemiol Drug Saf. 2009; 18: 437-447
        • Wells K.E.
        • Peterson E.L.
        • Ahmedani B.K.
        • Severson R.K.
        • Gleason-Comstock J.
        • Williams L.K.
        The relationship between combination inhaled corticosteroid and long-acting beta-agonist use and severe asthma exacerbations in a diverse population.
        J Allergy Clin Immunol. 2012; 129: 1274-1279
        • Singer N.
        Study raises questions about cholesterol drug’s benefit.
        The New York Times. November 16, 2009; : A16
        • Steiner J.F.
        • Prochazka A.V.
        The assessment of refill compliance using pharmacy records: methods, validity, and applications.
        J Clin Epidemiol. 1997; 50: 105-116
        • Williams L.K.
        • Joseph C.L.
        • Peterson E.L.
        • Wells K.
        • Wang M.
        • Chowdhry V.K.
        • Walsh M.
        • Campbell J.
        • Rand C.S.
        • Apter A.J.
        • Lanfear D.E.
        • Tunceli K.
        • Pladevall M.
        Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonadherence.
        J Allergy Clin Immunol. 2007; 120: 1153-1159
        • Weng T.C.
        • Yang Y.H.
        • Lin S.J.
        • Tai S.H.
        A systematic review and meta-analysis on the therapeutic equivalence of statins.
        J Clin Pharm Ther. 2010; 35: 139-151
        • Coresh J.
        • Astor B.C.
        • Greene T.
        • Eknoyan G.
        • Levey A.S.
        Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey.
        Am J Kidney Dis. 2003; 41: 1-12
        • Allison P.D.
        Discrete-time methods for the analysis of event histories.
        Sociol Methodol. 1982; 13: 61-98
        • Allison P.D.
        Analysis of tied or discrete data with the LOGISTIC, PROBIT, and GENMOD procedures.
        in: Survival Analysis Using the SAS System: A Practical Guide. SAS Institute Inc., Cary, North Carolina1995: 211-231
        • SAS Institute Inc
        SAS/STAT Users Guide. Version 9.2 ed.
        SAS Institute Inc., Cary, North Carolina2008
        • O’Brien R.G.
        Using the SAS system to perform power analyses for log-linear models.
        in: Proceedings of the Eleventh Annual SAS Users Group International Conference. SAS Institute Inc., Cary, North Carolina1986: 778-782
        • Divine G.
        • Kapke A.
        • Havstad S.
        • Joseph C.L.
        Exemplary data set sample size calculation for Wilcoxon-Mann-Whitney tests.
        Stat Med. 2010; 29: 108-115
        • Downs J.R.
        • Clearfield M.
        • Weis S.
        • Whitney E.
        • Shapiro D.R.
        • Beere P.A.
        • Langendorfer A.
        • Stein E.A.
        • Kruyer W.
        • Gotto Jr., A.M.
        Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS.
        JAMA. 1998; 279: 1615-1622
        • Shepherd J.
        • Cobbe S.M.
        • Ford I.
        • Isles C.G.
        • Lorimer A.R.
        • MacFarlane P.W.
        • McKillop J.H.
        • Packard C.J.
        • West of Scotland Coronary Prevention Study Group
        Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
        N Engl J Med. 1995; 333: 1301-1307
      1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344: 1383-1389
        • Sacks F.M.
        • Pfeffer M.A.
        • Moye L.A.
        • Rouleau J.L.
        • Rutherford J.D.
        • Cole T.G.
        • Brown L.
        • Warnica J.W.
        • Arnold J.M.
        • Wun C.C.
        • Davis B.R.
        • Braunwald E.
        • Cholesterol and Recurrent Events Trial Investigators
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        N Engl J Med. 1996; 335: 1001-1009
        • LaRosa J.C.
        • Grundy S.M.
        • Waters D.D.
        • Shear C.
        • Barter P.
        • Fruchart J.C.
        • Gotto A.M.
        • Greten H.
        • Kastelein J.J.
        • Shepherd J.
        • Wenger N.K.
        Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        N Engl J Med. 2005; 352: 1425-1435
        • Pedersen T.R.
        • Faergeman O.
        • Kastelein J.J.
        • Olsson A.G.
        • Tikkanen M.J.
        • Holme I.
        • Larsen M.L.
        • Bendiksen F.S.
        • Lindahl C.
        • Szarek M.
        • Tsai J.
        High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
        JAMA. 2005; 294: 2437-2445
        • Stein E.A.
        Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: more clarity or confusion?.
        J Am Coll Cardiol. 2008; 52: 2206-2209
        • Khanderia U.
        • Regal R.E.
        • Rubenfire M.
        • Boyden T.
        The ezetimibe controversy: implications for clinical practice.
        Ther Adv Cardiovasc Dis. 2011; 5: 199-208
        • Goldberger Z.D.
        • Valle J.A.
        • Dandekar V.K.
        • Chan P.S.
        • Ko D.T.
        • Nallamothu B.K.
        Are changes in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis.
        Am Heart J. 2010; 160: 701-714
        • Costanzo P.
        • Perrone-Filardi P.
        • Vassallo E.
        • Paolillo S.
        • Cesarano P.
        • Brevetti G.
        • Chiariello M.
        Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials.
        J Am Coll Cardiol. 2010; 56: 2006-2020
        • Lorenz M.W.
        • Polak J.F.
        • Kavousi M.
        • Mathiesen E.B.
        • Volzke H.
        • Tuomainen T.P.
        • Sander D.
        • Plichart M.
        • Catapano A.L.
        • Robertson C.M.
        • Kiechl S.
        • Rundek T.
        • Desvarieux M.
        • Lind L.
        • Schmid C.
        • DasMahapatra P.
        • Gao L.
        • Ziegelbauer K.
        • Bots M.L.
        • Thompson S.G.
        Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data.
        Lancet. 2012; 379: 2053-2062
        • Morrone D.
        • Weintraub W.S.
        • Toth P.P.
        • Hanson M.E.
        • Lowe R.S.
        • Lin J.
        • Shah A.K.
        • Tershakovec A.M.
        Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.
        Atherosclerosis. 2012; 223: 251-261
        • Glynn R.J.
        • Schneeweiss S.
        • Sturmer T.
        Indications for propensity scores and review of their use in pharmacoepidemiology.
        Basic Clin Pharmacol Toxicol. 2006; 98: 253-259
        • Joffe M.M.
        • Rosenbaum P.R.
        Invited commentary: propensity scores.
        Am J Epidemiol. 1999; 150: 327-333